S-EPMC12000221 - Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study. - OmicsDI

Unknown

Dataset Information

Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study.

ABSTRACT:

SUBMITTER: Zhang X

PROVIDER: S-EPMC12000221 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature